{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:47:14Z","timestamp":1791798434624,"version":"4.3.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health and Care Research","award":["NIHR133719"],"award-info":[{"award-number":["NIHR133719"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/05"],"award-info":[{"award-number":["MC_UU_00004\/05"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is limited information in the existing literature regarding the choice of oxazolidinone in clinical practice to treat infections caused by staphylococcal species. As members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) we have collaborated and written this narrative review aimed at clinicians considering these agents in practice. The review focuses on two medications, linezolid and tedizolid, with a comprehensive description of pharmacology aspects, adverse effects, drug interactions and contraindications, and we investigate the potential for treatment optimization. We anticipate that this article will provide support for those considering utilization of linezolid and tedizolid in clinical practice to treat staphylococcal species.<\/jats:p>","DOI":"10.1093\/jac\/dkag323","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:34:45Z","timestamp":1789673685000},"source":"Crossref","is-referenced-by-count":0,"title":["Oxazolidinones in the Clinical Management of Staphylococcal Infection\u2014Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6025-0878","authenticated-orcid":false,"given":"Liana","family":"Macpherson","sequence":"first","affiliation":[{"name":"Department of Infection, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]},{"name":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Grete","family":"Martson","sequence":"additional","affiliation":[{"name":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)"},{"name":"Leiden Academic Centre for Drug Research, Leiden University , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L","family":"Del Pozo","sequence":"additional","affiliation":[{"name":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)"},{"name":"Department of Infectious Diseases and Clinical Microbiology, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"IdiSNA, Navarra Institute for Health Research , Navarra ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Infection, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-9017","authenticated-orcid":false,"given":"Anna L","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Infection, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]},{"name":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS)"},{"name":"Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London , London ,","place":["UK"]},{"name":"Department of Infection, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026101205060445900_dkag323-B1","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/molecules26144280","article-title":"Oxazolidinone antibiotics: chemical, biological and analytical aspects","volume":"26","author":"Foti","year":"2021","journal-title":"Molecules"},{"key":"2026101205060445900_dkag323-B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.37201\/req\/s01.06.2021","article-title":"Tedizolid: new data and experiences for clinical practice","volume":"34","author":"Salavert Llet\u00ed","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"2026101205060445900_dkag323-B3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijantimicag.2003.11.003","article-title":"Oxazolidinones: activity, mode of action, and mechanism of resistance","volume":"23","author":"Bozdogan","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"2026101205060445900_dkag323-B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus","volume":"68","author":"Gu","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1469-0691.2004.01036.x","article-title":"Surveillance of linezolid resistance in Germany, 2001\u20132002","volume":"11","author":"Brauers","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"2026101205060445900_dkag323-B6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00609-17","article-title":"Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important gram-positive cocci in the United States from the LEADER surveillance program (2011 to 2015)","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12879-024-09376-z","article-title":"Characterization of linezolid- and methicillin-resistant coagulase-negative staphylococci in a tertiary hospital in China","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026101205060445900_dkag323-B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.diagmicrobio.2016.10.009","article-title":"Surveillance of tedizolid activity and resistance: in vitro susceptibility of gram-positive pathogens collected over 5 years from the United States and Europe","volume":"87","author":"Bensaci","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026101205060445900_dkag323-B9","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac088","article-title":"Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the surveillance of tedizolid activity and resistance (STAR) programme","volume":"4","author":"Carvalhaes","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026101205060445900_dkag323-B10","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1128\/AAC.45.7.2154-2156.2001","article-title":"Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci","volume":"45","author":"Prystowsky","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1365-2958.2007.05744.x","article-title":"Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid","volume":"64","author":"Toh","year":"2007","journal-title":"Mol Microbiol"},{"key":"2026101205060445900_dkag323-B12","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/jac\/dky088","article-title":"Characterization of poxtA, a novel phenicol\u2013oxazolidinone\u2013tetracycline resistance gene from an MRSA of clinical origin","volume":"73","author":"Antonelli","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/jac\/dkw040","article-title":"Co-location of the oxazolidinone resistance genes optrA and cfr on a multiresistance plasmid from Staphylococcus sciuri","volume":"71","author":"Li","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.diagmicrobio.2016.02.008","article-title":"In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci","volume":"85","author":"Silva-Del Toro","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026101205060445900_dkag323-B15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid","volume":"71","author":"Barber","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or \u03b2-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2026101205060445900_dkag323-B17","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026101205060445900_dkag323-B19","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026101205060445900_dkag323-B20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/23744235.2019.1642510","article-title":"Linezolid in the treatment of periprosthetic joint infection caused by coagulase-negative staphylococci","volume":"51","author":"Eriksson","year":"2019","journal-title":"Infect Dis"},{"key":"2026101205060445900_dkag323-B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5194\/jbji-6-7-2020","article-title":"Clinical use of linezolid in periprosthetic joint infections\u2014a systematic review","volume":"6","author":"Theil","year":"2020","journal-title":"J Bone Jt Infect"},{"key":"2026101205060445900_dkag323-B22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"2026101205060445900_dkag323-B23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2026101205060445900_dkag323-B24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-20","article-title":"Safety and tolerability of more than six days of tedizolid treatment","volume":"64","author":"Mensa Vendrell","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B25","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01282-23","article-title":"Safety and tolerability of tedizolid as oral treatment for bone and joint infections","volume":"11","author":"Miller","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026101205060445900_dkag323-B26","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2026101205060445900_dkag323-B27","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B28","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1128\/AAC.03431-14","article-title":"Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B29","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1128\/JCM.03395-15","article-title":"New gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides","volume":"54","author":"Crotty","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2026101205060445900_dkag323-B30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jsps.2019.09.002","article-title":"Determining therapeutic trough ranges for linezolid","volume":"27","author":"Alsultan","year":"2019","journal-title":"Saudi Pharm J"},{"key":"2026101205060445900_dkag323-B31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00687-17","article-title":"Systematic therapeutic drug monitoring for linezolid: variability and clinical impact","volume":"61","author":"Galar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B32","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2026101205060445900_dkag323-B33","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B34","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2026101205060445900_dkag323-B35","doi-asserted-by":"publisher","first-page":"106783","DOI":"10.1016\/j.ijantimicag.2023.106783","article-title":"LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring","volume":"61","author":"Lau","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026101205060445900_dkag323-B36","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"},{"key":"2026101205060445900_dkag323-B37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026101205060445900_dkag323-B38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01619-20","article-title":"Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections","volume":"65","author":"Blackman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B39","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1016\/S1473-3099(25)00155-0","article-title":"The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments","volume":"25","author":"M\u00e4rtson","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026101205060445900_dkag323-B40","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1128\/AAC.00682-16","article-title":"Pharmacokinetics of tedizolid in morbidly obese and covariate-matched nonobese adults","volume":"60","author":"Pai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/jac\/dks431","article-title":"Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?","volume":"68","author":"Hamilton","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B42","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1517\/17425255.2015.1098617","article-title":"Drug\u2013drug interactions and safety of linezolid, tedizolid, and other oxazolidinones","volume":"11","author":"Douros","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026101205060445900_dkag323-B43","author":"Merck Sharp & Dohme (UK) Limited"},{"key":"2026101205060445900_dkag323-B44","author":"Amarox Limited"},{"key":"2026101205060445900_dkag323-B45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00228-023-03500-9","article-title":"Linezolid-associated serotonin toxicity: a systematic review","volume":"79","author":"Elbarbry","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2026101205060445900_dkag323-B46","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/jac\/dkr467","article-title":"Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data","volume":"67","author":"Butterfield","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2026101205060445900_dkag323-B47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00228-020-02990-1","article-title":"Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic\/pharmacodynamic analysis","volume":"77","author":"Gatti","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2026101205060445900_dkag323-B48","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/ciad357","article-title":"Antibiotic myths for the infectious diseases clinician","volume":"77","author":"McCreary","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026101205060445900_dkag323-B49","doi-asserted-by":"publisher","first-page":"106843","DOI":"10.1016\/j.ijantimicag.2023.106843","article-title":"Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents","volume":"62","author":"Kufel","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026101205060445900_dkag323-B50","doi-asserted-by":"publisher","first-page":"e2247426","DOI":"10.1001\/jamanetworkopen.2022.47426","article-title":"Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants","volume":"5","author":"Bai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026101205060445900_dkag323-B51","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1128\/AAC.00431-13","article-title":"In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions","volume":"57","author":"Flanagan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B52","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00870-24","article-title":"Incidence of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents","volume":"68","author":"Fang","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B53","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1183\/09031936.00001913","article-title":"Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients","volume":"42","author":"Bolhuis","year":"2013","journal-title":"Eur Respir J"},{"key":"2026101205060445900_dkag323-B54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1086\/498509","article-title":"High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease","volume":"42","author":"Wu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026101205060445900_dkag323-B55","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1128\/AAC.02856-14","article-title":"Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism","volume":"58","author":"Del Pozo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101205060445900_dkag323-B56","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14740338.2017.1335305","article-title":"Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes","volume":"16","author":"Santini","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2026101205060445900_dkag323-B57","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac028","article-title":"Real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success","volume":"9","author":"Morrisette","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026101205060445900_dkag323-B58","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/jac\/dkx159","article-title":"Linezolid and lactation: measurement of drug levels in breast milk and the nursing infant","volume":"72","author":"Lim","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag323\/71859899\/dkag323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag323\/71859899\/dkag323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:06:08Z","timestamp":1791795968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag323\/8909096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag323","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,6]]},"article-number":"dkag323"}}